DN-108, a thiazolidinedione derivative, acts as an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic properties. It improves hyperglycemia, hypertriglyceridemia, and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increases 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity, making it a promising candidate for type 2 diabetes research.